Concordia Healthcare Corp (CXRX) was Downgraded by CIBC to ” Sector Underperform”. Earlier the firm had a rating of “Sector Perform ” on the company shares. CIBC advised their investors in a research report released on Aug 15, 2016.
Many Wall Street Analysts have commented on Concordia Healthcare Corp. Concordia Healthcare Corp was Downgraded by TD Securities to ” Hold” on Aug 4, 2016. Concordia Healthcare Corp was Initiated by Goldman to “Neutral” on Jun 6, 2016.
On the company’s financial health, Concordia Healthcare Corp reported $1.38 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Aug 12, 2016. Analyst had a consensus of $1.40. The company had revenue of $231.70 million for the quarter, compared to analysts expectations of $232.57 million. The company’s revenue was up 208.1% compared to the same quarter last year.
Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.